Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Johnson

Showing results (211-220 of 244) with videos related to

Pageof 25
Sort By:
British Journal of Cancer|January 25, 2023
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer careMaria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Gerontology|November 30, 2022
Two Years with COVID-19: The Electronic Frailty Index Identifies High-Risk Patients in the Stockholm GeroCovid StudyJonathan K L Mak, Maria Eriksdotter, Martin Annetorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Leukemia|March 24, 2018
Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphomaShamzah Araf, Jun Wang, Koorosh Korfi, et al.
Leukemia|March 24, 2019
Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphomaShamzah Araf, Jun Wang, Koorosh Korfi, et al.
The EMBO Journal|June 23, 2014
Molecular mechanism of ligand recognition by membrane transport protein, Mhp1Katie J Simmons, Scott M Jackson, Florian Brueckner, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Haematologica|July 7, 2018
Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplantShamzah Araf, Jun Wang, Margaret Ashton-Key, et al.
Pageof 25

Showing results (211-220 of 244) with videos related to

Sort By:
Pageof 25
British Journal of Cancer|January 25, 2023
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer careMaria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Gerontology|November 30, 2022
Two Years with COVID-19: The Electronic Frailty Index Identifies High-Risk Patients in the Stockholm GeroCovid StudyJonathan K L Mak, Maria Eriksdotter, Martin Annetorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Leukemia|March 24, 2018
Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphomaShamzah Araf, Jun Wang, Koorosh Korfi, et al.
Leukemia|March 24, 2019
Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphomaShamzah Araf, Jun Wang, Koorosh Korfi, et al.
The EMBO Journal|June 23, 2014
Molecular mechanism of ligand recognition by membrane transport protein, Mhp1Katie J Simmons, Scott M Jackson, Florian Brueckner, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Haematologica|July 7, 2018
Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplantShamzah Araf, Jun Wang, Margaret Ashton-Key, et al.
Pageof 25